ABSTRACT
Exposure to prescription opioids can lead to opioid use disorder (OUD) in some individuals, but we lack scalable tools to predict who is at risk. We collected retrospective data on the initial subjective effects of prescription opioids from 117,508 research participants, 5.3% of whom self-reported OUD. Positive subjective effects, particularly “Like Overall”, “Euphoric”, and “Energized”, were the strongest predictors of OUD. For example, the odds-ratio for individuals responding “Extremely” for “Like Overall” was 36.2. The sensitivity and specificity of this single question was excellent (ROC=0.87). Negative effects and analgesic effects were much less predictive. We present a two-step decision tree that can identify a small high-risk subset with 77.4% prevalence of OUD and a much larger low-risk subset with 1.7% prevalence of OUD. Our results demonstrate that positive subjective responses are predictive of future misuse and suggest that vulnerable individuals may be identified and targeted for preventative interventions.
Competing Interest Statement
MM, VT, and KB are employed by and hold stock or stock options in 23andMe, Inc. NCK is consultant and holds stock options in CARI Health, Inc. CM is a consultant, scientific advisory board member, and stock options holder in CARI Health, Inc. HdW is a member of the Board of Directors in PharmAla Biotech (not related to this paper).
Funding Statement
This work was supported by National Institutes of Health grant numbers DP1DA054394 (JG, JJM, SSR), R01DA061977 (AAP, SSR), P50DA037844 (EOJ, AAP, SSR), T32GM139790 (JG) and R25MH081482 (LV-R).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
External Association for Accreditation of Human Research Protection Programs- accredited Salus IRB gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos